Efficacy and Safety of MLC601 in the Treatment of Mild Cognitive Impairment: A Pilot, Randomized, Double-Blind, Placebo-Controlled Study

Abbasi M; Pakdaman H; Ashrafi F; Delavar?Kasmaei H; Assarzadegan F; Arabahmadi M; Gharagozli K; Amini?Harandi A; Behnam B

首页> 外文期刊>Dementia and Geriatric Cognitive Disorders Extra >Efficacy and Safety of MLC601 in the Treatment of Mild Cognitive Impairment: A Pilot, Randomized, Double-Blind, Placebo-Controlled Study

【24h】

Efficacy and Safety of MLC601 in the Treatment of Mild Cognitive Impairment: A Pilot, Randomized, Double-Blind, Placebo-Controlled Study

机译：MLC601在治疗轻度认知障碍中的功效和安全性：一项先行，随机，双盲，安慰剂对照研究

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background and Aim: Mild cognitive impairment (MCI) is characterized by declined cognitive function greater than that expected for a person?￠??s age. The clinical significance of this condition is its possible progression to dementia. MLC601 is a natural n

机译：背景与目的：轻度认知障碍（MCI）的特征是认知功能下降的幅度大于人们预期的年龄。这种情况的临床意义是它可能发展为痴呆。 MLC601是天然的

著录项

来源
《Dementia and Geriatric Cognitive Disorders Extra》 |2017年第1期|共页
作者
Abbasi M; Pakdaman H; Ashrafi F; Delavar?Kasmaei H; Assarzadegan F; Arabahmadi M; Gharagozli K; Amini?Harandi A; Behnam B;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类临床医学;
关键词

相似文献

外文文献
中文文献
专利

1. The effectiveness and safety of Kami Guibi-tang for mild cognitive impairment: study protocol of a pilot, randomized, placebo-controlled, double-blind trial [J] . Hee-Yeon Shin, Jeong-Hwa Kim, Geon-Ho Jahng, Trials . 2019,第1期

机译：KAMI Guibi-Tang对轻度认知障碍的效力和安全：试验，随机，安慰剂控制，双盲试验的研究协议
2. A randomized, double-blind, placebo-controlled study on long-term efficacy and safety of ipragliflozin treatment in patients with type 2 diabetes mellitus and renal impairment: results of the Long-Term ASP1941 Safety Evaluation in Patients with Type 2 Diabetes with Renal Impairment (LANTERN) study [J] . Kashiwagi A., Takahashi H., Ishikawa H., Diabetes, obesity & metabolism . 2015,第2期

机译：一项关于伊格列净治疗2型糖尿病和肾功能不全患者的长期疗效和安全性的随机，双盲，安慰剂对照研究：对患有肾功能不全的2型糖尿病患者进行长期ASP1941安全性评估的结果（LANTERN）研究
3. Efficacy and safety of Ginkgo biloba extract EGb 761? in mild cognitive impairment with neuropsychiatric symptoms: A randomized, placebo-controlled, double-blind, multicenter trial [J] . GavrilovaS.I., PreussU.W., WongJ.W.M., International journal of geriatric psychiatry . 2014,第10期

机译：银杏叶提取物EGB 761的功效和安全性？神经精神症状的轻度认知障碍患者：一项随机，安慰剂对照，双盲，多中心试验
4. MULTI-CENTER, PLACEBO-CONTROLLED, DOUBLE-BLIND, RANDOMIZED STUDY OF ORAL TOCERANIB PHOSPHATE (PALLADIATM, SU11654), A RECEPTOR TYROSINE KINASE INHIBITOR, FOR THE TREATMENT OF DOGS WITH RECURRENT MAS [C] . Cheryl L London, Carolyn J Henry, Anthony W Rusk, Annual conference of the Veterinary Cancer Society . 2008

机译：多中心，安慰剂对照，双盲，随机研究口服Toceranib磷酸盐（Palladia TM，SU11654），受体酪氨酸激酶抑制剂，用于治疗经常性MAS的狗
5. A double-blind, randomized comparison of the cognitive/psychomotor and inferred driving impairment side effects of a single, mild, dose of oxycodone or placebo among elderly and young individuals. [D] . Lowery, Charles D. 2005

机译：老年人和年轻人中单次，轻度剂量的羟考酮或安慰剂的认知/心理运动和推断的驾驶障碍副作用的双盲，随机比较。
6. Efficacy and Safety of MLC601 in the Treatment of Mild Cognitive Impairment: A Pilot Randomized Double-Blind Placebo-Controlled Study [O] . Hossein Pakdaman, Ali Amini Harandi, Mehdi Abbasi, 2017

机译：MLC601在治疗轻度认知障碍中的功效和安全性：一项先行随机双盲安慰剂对照研究
7. Efficacy and Safety of MLC601 in the Treatment of Mild Cognitive Impairment: A Pilot, Randomized, Double-Blind, Placebo-Controlled Study [O] . Hossein Pakdaman, Ali Amini Harandi, Mehdi Abbasi, 2017

机译：mLC601治疗轻度认知障碍的疗效和安全性：一项试验性，随机，双盲，安慰剂对照研究

Efficacy and Safety of MLC601 in the Treatment of Mild Cognitive Impairment: A Pilot, Randomized, Double-Blind, Placebo-Controlled Study

摘要

著录项

相似文献

相关主题

期刊订阅